QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,066 signal articles · 513 in last 24h · 103,602 total before filter · latest 1h ago
513last 24h
2497last 7d
481● bullish (7d)
255● bearish (7d)
197publishers
AllMacro237Earnings1472M&A141Regulatory15Product4Analyst29
✕ clear all filtersticker: JNJsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
J&J Has No Plans to Enter Obesity Drugs Market, CEO Says
Bloomberg48d agoneutralVIDEO
J&J Has No Plans to Enter Obesity Drugs Market, CEO Says

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I’m Loading Up on Anyway
24/7 Wall St.55d agoneutral
The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I’m Loading Up on Anyway

I keep buying Johnson & Johnson (NYSE:JNJ) because the market keeps handing me a discount on a company that refuses to act like the slow, sleepy legacy name Wall Street wants to price it as. The Fed will say what it says this month. The headlines will do what headlines do. I am still hitting ... The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I’m Loading Up on Anyway

Johnson & Johnson bets $1 billion on hard-to-treat cancer
TheStreet55d agoneutral
Johnson & Johnson bets $1 billion on hard-to-treat cancer

Johnson & Johnson (JNJ) is one of the biggest names in health care, and lately, its stock has been living up to the hype. Shares have climbed back toward record territory, while much of the market has been affected by a sharp sell-off in technology stocks. Now, the company is pumping fresh cash ...

Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes
24/7 Wall St.57d agoneutral
Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes

Five thousand dollars a month in spendable dividend income works out to $60,000 per year after federal tax, roughly equivalent to the salary of a typical police officer in Indiana. The headline yield shown on a brokerage statement does not tell the full story. Taxes, the type of distributions received, and future dividend growth all ... Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes

How to Maximize Dividend Income in Retirement Before RMDs Change the Math
24/7 Wall St.62d agoneutral
How to Maximize Dividend Income in Retirement Before RMDs Change the Math

At the 24% federal bracket, a portfolio throwing off $40,000 in high-yield dividend income hands roughly $9,600 to the IRS every year when those shares sit in a taxable account treated as ordinary income. For investors in the gap years between retirement and RMD age 73, that drag compounds quietly until required minimum distributions force ... How to Maximize Dividend Income in Retirement Before RMDs Change the Math

This Is What a $1 Million Dividend Portfolio Pays After Taxes
24/7 Wall St.63d agoneutral
This Is What a $1 Million Dividend Portfolio Pays After Taxes

At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what ... This Is What a $1 Million Dividend Portfolio Pays After Taxes

J&J’s Strategy for Deals on the Cheap Faces a Big Test
The Wall Street Journal69d agoneutral
J&J’s Strategy for Deals on the Cheap Faces a Big Test

Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices.

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
The Wall Street Journal69d agoneutral
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.

Inflation Adjusted Dividend Income: How to Replace $80,000 in Today’s Dollars 20 Years From Now
24/7 Wall St.71d agoneutral
Inflation Adjusted Dividend Income: How to Replace $80,000 in Today’s Dollars 20 Years From Now

A 50-year-old woman planning to retire at 70 on the equivalent of $80,000 in today’s purchasing power is actually targeting a much larger nominal income figure. Assuming long-run inflation averages 3% annually, maintaining that same lifestyle 20 years from now would require roughly $144,500 per year in nominal dollars. That is the income her portfolio needs ... Inflation Adjusted Dividend Income: How to Replace $80,000 in Today’s Dollars 20 Years From Now

What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California
24/7 Wall St.72d agoneutral
What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California

A California retiree with a $1 million dividend portfolio earning a 5% blended yield grosses $50,000 in annual income. After federal qualified-dividend tax and California’s state income tax, that number drops sharply. California treats dividends as ordinary income at the state level, with marginal rates running from 9.3% to 13.3%. The math is what separates ... What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California

You Do Not Need 30 Years of Federal Service to Build a Pension. Here Is the $495,000 Dividend Portfolio That Pays Like One
24/7 Wall St.76d agoneutral
You Do Not Need 30 Years of Federal Service to Build a Pension. Here Is the $495,000 Dividend Portfolio That Pays Like One

A federal employee retiring at 62 after 30 years of service with a “high-3” salary average of $90,000 would receive an estimated FERS basic pension benefit of roughly $29,700 annually, based on the standard formula: 1.1% × 30 years × $90,000. For private-sector workers without access to a defined-benefit pension, that figure provides a useful ... You Do Not Need 30 Years of Federal Service to Build a Pension. Here Is the $495,000 Dividend Portfolio That Pays Like One

Stereotaxis Q1 Earnings Call Highlights
MarketBeat81d agoneutral
Stereotaxis Q1 Earnings Call Highlights

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system. Chairman and CEO David Fischel told investors that t

The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
24/7 Wall St.84d agoneutral
The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio

S&P Global rates only two U.S. public companies AAA, one notch above the federal government itself. S&P downgraded the United States to AA+ in 2011, and Fitch followed in 2023, leaving Uncle Sam a step below the small club still graded at the top of the scale. That club has two members: Johnson & Johnson ... The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
24/7 Wall St.84d agoneutral
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More

Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inflation, which soared to 3.8% annually, the highest since May 2023, while the core number, which is less food and energy, rose to ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap

A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job
24/7 Wall St.88d agoneutral
A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job

A full-time federal minimum wage worker in the United States earns $7.25 an hour, or about $15,080 a year before taxes, working 40 hours a week for 52 weeks. The question for anyone with capital: what does it take to clear that bar without having to ask anyone, “Do you want fries with that?” On ... A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job

J & J Snack Foods Q2 Earnings Call Highlights
MarketBeat90d agoneutral
J & J Snack Foods Q2 Earnings Call Highlights

J & J Snack Foods (NASDAQ:JJSF) reported fiscal second-quarter 2026 results that showed margin expansion and higher adjusted earnings despite a decline in sales, as management pointed to benefits from its “Project Apollo” transformation and ongoing portfolio reshaping. Chief Executive Officer D

How High Will Intel Stock Go?
The Wall Street Journal91d agoneutral
How High Will Intel Stock Go?

After another dizzying rally yesterday, Intel shares closed at $108.15 a share. With the latest 13% gain, the back-in-favor-again chip giant can claim these accolades: Its market cap of $544 billion, a record for the company, now exceeds that of Oracle and Johnson & Johnson, according to Dow Jones Market Data.